Faes Farma’s strong performance was attributable to the solid performance in the domestic markets, along with the continued demand for Bilastine (globally) and Hidroferol. An increasing contribution of the licensing revenue (which typically carry a higher-margin) from Bilastine and other drugs trickled down to profitability – net margin up by ~2ppt to 16.9%. Given this performance, we believe that the company would be able to achieve its FY19 guidance.
16 May 2019
Robust performance in Q1 19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust performance in Q1 19
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
16 May 2019 -
Author:
Kamla Singh -
Pages:
3
Faes Farma’s strong performance was attributable to the solid performance in the domestic markets, along with the continued demand for Bilastine (globally) and Hidroferol. An increasing contribution of the licensing revenue (which typically carry a higher-margin) from Bilastine and other drugs trickled down to profitability – net margin up by ~2ppt to 16.9%. Given this performance, we believe that the company would be able to achieve its FY19 guidance.